BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis 2018;12:1753465817750524. [PMID: 29355081 DOI: 10.1177/1753465817750524] [Cited by in Crossref: 70] [Cited by in F6Publishing: 84] [Article Influence: 23.3] [Reference Citation Analysis]
Number Citing Articles
1 Sethi S. Is It the Heart or the Lung? Sometimes It Is Both. JAHA. [DOI: 10.1161/jaha.122.027112] [Reference Citation Analysis]
2 Gregory A, Xu Z, Pratte K, Lee S, Liu C, Chase R, Yun J, Saferali A, Hersh CP, Bowler R, Silverman E, Castaldi PJ, Boueiz A. Clustering-based COPD subtypes have distinct longitudinal outcomes and multi-omics biomarkers. BMJ Open Respir Res 2022;9:e001182. [PMID: 35999035 DOI: 10.1136/bmjresp-2021-001182] [Reference Citation Analysis]
3 Balbirsingh V, Mohammed AS, Turner AM, Newnham M. Cardiovascular disease in chronic obstructive pulmonary disease: a narrative review. Thorax 2022:thoraxjnl-2021-218333. [PMID: 35772939 DOI: 10.1136/thoraxjnl-2021-218333] [Reference Citation Analysis]
4 Qiu Y, Wang Y, Shen N, Wang Q, Chai L, Wang J, Zhang Q, Chen Y, Liu J, Li D, Chen H, Li M. Nomograms for Predicting Coexisting Cardiovascular Disease and Prognosis in Chronic Obstructive Pulmonary Disease: A Study Based on NHANES Data. Can Respir J 2022;2022:5618376. [PMID: 35721788 DOI: 10.1155/2022/5618376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zinellu A, Zinellu E, Pau MC, Carru C, Pirina P, Fois AG, Mangoni AA. A Comprehensive Systematic Review and Meta-Analysis of the Association between the Neutrophil-to-Lymphocyte Ratio and Adverse Outcomes in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. J Clin Med 2022;11:3365. [PMID: 35743436 DOI: 10.3390/jcm11123365] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Cai X, Ma B, Kourmatzis A, Salehi F, Lee A, Farina D, Chan K, Cheng S. Potential effects of inhaler mouthpiece size on particle deposition in the human upper airway. Aerosol Science and Technology. [DOI: 10.1080/02786826.2022.2086034] [Reference Citation Analysis]
7 Hammond MM, Everitt IK, Khan SS. New strategies and therapies for the prevention of heart failure in high-risk patients. Clin Cardiol 2022;45 Suppl 1:S13-25. [PMID: 35789013 DOI: 10.1002/clc.23839] [Reference Citation Analysis]
8 Brassington K, Selemidis S, Bozinovski S, Vlahos R. Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics. Clin Sci (Lond) 2022;136:405-23. [PMID: 35319068 DOI: 10.1042/CS20210835] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Bruin MM, Deijkers RLM, Bus MPA, van Elzakker EPM, Bazuin R, Nelissen RG, Pijls BG. Inhaled Corticosteroids, Vitamin K Antagonists and Amlodipine Were Associated with an Increased Risk of Acute Periprosthetic Joint Infection in Patients with Total Hip Arthroplasty: A Retrospective Case–Cohort Study. JCM 2022;11:1842. [DOI: 10.3390/jcm11071842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Solidoro P, Albera C, Ribolla F, Bellocchia M, Brussino L, Patrucco F. Triple Therapy in COPD: Can We Welcome the Reduction in Cardiovascular Risk and Mortality? Front Med 2022;9:816843. [DOI: 10.3389/fmed.2022.816843] [Reference Citation Analysis]
11 Alves L, Pullen R, Hurst JR, Miravitlles M, Carter V, Chen R, Couper A, Dransfield M, Evans A, Hardjojo A, Jones D, Jones R, Kerr M, Kostikas K, Marshall J, Martinez F, van Melle M, Murray R, Muro S, Nordon C, Pollack M, Price C, Sharma A, Singh D, Winders T, Price DB. CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients. PROM 2022;Volume 13:53-68. [DOI: 10.2147/prom.s296506] [Reference Citation Analysis]
12 Braido F, Corsico AG, Paleari D, Piraino A, Cavalieri L, Scichilone N. Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution. Ther Adv Respir Dis 2022;16:17534666211066063. [PMID: 35044875 DOI: 10.1177/17534666211066063] [Reference Citation Analysis]
13 Müllerová H, Marshall J, de Nigris E, Varghese P, Pooley N, Embleton N, Nordon C, Marjenberg Z. Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis. Ther Adv Respir Dis 2022;16:17534666221113647. [PMID: 35894441 DOI: 10.1177/17534666221113647] [Reference Citation Analysis]
14 Amin AN, Cornelison S, Woods JA, Hanania NA. Managing hospitalized patients with a COPD exacerbation: the role of hospitalists and the multidisciplinary team. Postgrad Med 2021;:1-8. [PMID: 34913814 DOI: 10.1080/00325481.2021.2018257] [Reference Citation Analysis]
15 Smith MC, Ashdown HF, Sheppard JP, Butler CC, Bankhead C. Statin prescription in patients with chronic obstructive pulmonary disease and risk of exacerbations: a retrospective cohort study in the Clinical Practice Research Datalink. BMJ Open 2021;11:e050757. [PMID: 34876426 DOI: 10.1136/bmjopen-2021-050757] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Damkjær M, Suppli Ulrik C, Godtfredsen N, Håkansson KEJ. Beta-Blockers in High-Risk Outpatients with Chronic Obstructive Pulmonary Disease are Associated with All-Cause Mortality - The STATUETTE Cohort Study. Int J Chron Obstruct Pulmon Dis 2021;16:2397-406. [PMID: 34465987 DOI: 10.2147/COPD.S315151] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Shi Y, Zhang J, Huang Y. Prediction of cardiovascular risk in patients with chronic obstructive pulmonary disease: a study of the National Health and Nutrition Examination Survey database. BMC Cardiovasc Disord 2021;21:417. [PMID: 34470611 DOI: 10.1186/s12872-021-02225-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Kalaycıoğlu E, Çetin M, Kırış T, Özyıldız AG, Turan T, Yılmaz AS. FEV1 is independently related with impaired left atrial strain in chronic obstructive pulmonary disease patients: A speckle tracking study. Clin Respir J 2021. [PMID: 34435743 DOI: 10.1111/crj.13442] [Reference Citation Analysis]
19 Stromsnes K, Lagzdina R, Olaso-Gonzalez G, Gimeno-Mallench L, Gambini J. Pharmacological Properties of Polyphenols: Bioavailability, Mechanisms of Action, and Biological Effects in In Vitro Studies, Animal Models, and Humans. Biomedicines 2021;9:1074. [PMID: 34440278 DOI: 10.3390/biomedicines9081074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
20 Pullen R, Miravitlles M, Sharma A, Singh D, Martinez F, Hurst JR, Alves L, Dransfield M, Chen R, Muro S, Winders T, Blango C, Muellerova H, Trudo F, Dorinsky P, Alacqua M, Morris T, Carter V, Couper A, Jones R, Kostikas K, Murray R, Price DB. CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care. Int J Chron Obstruct Pulmon Dis 2021;16:2301-22. [PMID: 34413639 DOI: 10.2147/COPD.S313498] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
21 Theodorakopoulou MP, Alexandrou ME, Bakaloudi DR, Pitsiou G, Stanopoulos I, Kontakiotis T, Boutou AK. Endothelial dysfunction in COPD: a systematic review and meta-analysis of studies using different functional assessment methods. ERJ Open Res 2021;7:00983-2020. [PMID: 34195258 DOI: 10.1183/23120541.00983-2020] [Reference Citation Analysis]
22 Kotlyarov S, Kotlyarova A. The Role of ABC Transporters in Lipid Metabolism and the Comorbid Course of Chronic Obstructive Pulmonary Disease and Atherosclerosis. Int J Mol Sci 2021;22:6711. [PMID: 34201488 DOI: 10.3390/ijms22136711] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
23 Ramos-nino ME, Maclean CD, Littenberg B. Association between Obstructive Lung Disease and Cardiovascular Disease: Results from the Vermont Diabetes Information System. JoR 2021;1:165-72. [DOI: 10.3390/jor1030016] [Reference Citation Analysis]
24 Kim H, Lee JT. Inter-mortality displacement hypothesis and short-term effect of ambient air pollution on mortality in seven major cities of South Korea: a time-series analysis. Int J Epidemiol 2021;49:1802-12. [PMID: 33211858 DOI: 10.1093/ije/dyaa181] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Patel J, Ladani A, Sambamoorthi N, Lemasters T, Dwibedi N, Sambamoorthi U. Predictors of Co-occurring Cardiovascular and Gastrointestinal Disorders among Elderly with Osteoarthritis. Osteoarthritis and Cartilage Open 2021;3:100148. [DOI: 10.1016/j.ocarto.2021.100148] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kim Y, Kim YJ, Kang YM, Cho WK. Exploring the impact of number and type of comorbidities on the risk of severe COPD exacerbations in Korean Population: a Nationwide Cohort Study. BMC Pulm Med 2021;21:151. [PMID: 33957924 DOI: 10.1186/s12890-021-01497-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Theodorakopoulou MP, Bakaloudi DR, Dipla K, Zafeiridis A, Boutou AK. Vascular endothelial damage in COPD: current functional assessment methods and future perspectives. Expert Rev Respir Med 2021;15:1121-33. [PMID: 33874819 DOI: 10.1080/17476348.2021.1919089] [Reference Citation Analysis]
28 Axson EL, Bottle A, Cowie MR, Quint JK. Relationship between heart failure and the risk of acute exacerbation of COPD. Thorax 2021:thoraxjnl-2020-216390. [PMID: 33927022 DOI: 10.1136/thoraxjnl-2020-216390] [Reference Citation Analysis]
29 Putcha N, Ozol-Godfrey A, Sanjar S, Sharma S. Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD. Int J Chron Obstruct Pulmon Dis 2021;16:1061-73. [PMID: 33907393 DOI: 10.2147/COPD.S302088] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Puddu PE, Menotti A, Kromhout D, Kafatos A, Tolonen H. Chronic bronchitis in the 50-year follow-up of the European cohorts of the Seven Countries Study: prevalence, mortality and association with cardiovascular diseases. Respir Med 2021;181:106385. [PMID: 33848923 DOI: 10.1016/j.rmed.2021.106385] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Theodorakopoulou MP, Bakaloudi DR, Alexandrou ME, Papakosta D, Pataka A, Kioumis I, Boutou AK. Endothelial Dysfunction during Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. COPD 2021;18:246-53. [PMID: 33779450 DOI: 10.1080/15412555.2021.1900094] [Reference Citation Analysis]
32 Kotlyarov S. Participation of ABCA1 Transporter in Pathogenesis of Chronic Obstructive Pulmonary Disease. Int J Mol Sci 2021;22:3334. [PMID: 33805156 DOI: 10.3390/ijms22073334] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
33 Furlan SF, Drager LF. To Dip or not to Dip Blood Pressure in Chronic Obstructive Pulmonary Disease: That is the Question! Arq Bras Cardiol 2021;116:303-4. [PMID: 33656079 DOI: 10.36660/abc.20201379] [Reference Citation Analysis]
34 Damkjær M, Håkansson K, Kallemose T, Ulrik CS, Godtfredsen N. Statins in High-Risk Chronic Obstructive Pulmonary Disease Outpatients: No Impact on Time to First Exacerbation and All-Cause Mortality - The STATUETTE Cohort Study. Int J Chron Obstruct Pulmon Dis 2021;16:579-89. [PMID: 33707941 DOI: 10.2147/COPD.S296472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
35 Whittaker HR, Bloom C, Morgan A, Jarvis D, Kiddle SJ, Quint JK. Accelerated FEV1 decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients. Eur Respir J 2021;57:2000918. [PMID: 32972984 DOI: 10.1183/13993003.00918-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
36 Carmona-Pírez J, Poblador-Plou B, Ioakeim-Skoufa I, González-Rubio F, Gimeno-Feliú LA, Díez-Manglano J, Laguna-Berna C, Marin JM, Gimeno-Miguel A, Prados-Torres A. Multimorbidity clusters in patients with chronic obstructive airway diseases in the EpiChron Cohort. Sci Rep 2021;11:4784. [PMID: 33637795 DOI: 10.1038/s41598-021-83964-w] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
37 Gulea C, Zakeri R, Alderman V, Morgan A, Ross J, Quint JK. Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison. Respir Res 2021;22:64. [PMID: 33622362 DOI: 10.1186/s12931-021-01661-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
38 Leong P, MacDonald MI, King PT, Osadnik CR, Ko BS, Landry SA, Hamza K, Kugenasan A, Troupis JM, Bardin PG. Treatable cardiac disease in hospitalised COPD exacerbations. ERJ Open Res 2021;7:00756-2020. [PMID: 34104641 DOI: 10.1183/23120541.00756-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
39 Huang YC, Lin TY, Wu HT, Chang PJ, Lo CY, Wang TY, Kuo CS, Lin SM, Chung FT, Lin HC, Hsieh MH, Lo YL. Cardiorespiratory coupling is associated with exercise capacity in patients with chronic obstructive pulmonary disease. BMC Pulm Med 2021;21:22. [PMID: 33435937 DOI: 10.1186/s12890-021-01400-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Kabbach EZ, Heubel AD, da Luz Goulart C, Di Lorenzo VAP, Phillips SA, Borghi-Silva A, Mendes RG. Association of exercise capacity and endothelial function in patients with severe exacerbations of chronic obstructive pulmonary disease. Sci Rep 2021;11:461. [PMID: 33432116 DOI: 10.1038/s41598-020-80601-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Fermont JM, Fisk M, Bolton CE, MacNee W, Cockcroft JR, Fuld J, Cheriyan J, Mohan D, Mäki-Petäjä KM, Al-Hadithi AB, Tal-Singer R, Müllerova H, Polkey MI, Wood AM, McEniery CM, Wilkinson IB; ERICA consortium. Cardiovascular risk prediction using physical performance measures in COPD: results from a multicentre observational study. BMJ Open 2020;10:e038360. [PMID: 33372069 DOI: 10.1136/bmjopen-2020-038360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
42 Li P, Dai Q, Cai P, Teng C, Pan S, Dixon RAF, Liu Q. Identifying different phenotypes in takotsubo cardiomyopathy by latent class analysis. ESC Heart Fail 2021;8:555-65. [PMID: 33244882 DOI: 10.1002/ehf2.13117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
43 Nies LM, Akker ILD, Rozendaal L, Baar B, Vos RC, Hart HE. The impact of the new Dutch guideline on cardiovascular risk management in patients with COPD: a retrospective study. BJGP Open 2021;5:bjgpopen20X101139. [PMID: 33199309 DOI: 10.3399/bjgpopen20X101139] [Reference Citation Analysis]
44 Ji Z, Hernández-Vázquez J, Domínguez-Zabaleta IM, Xia Z, Bellón-Cano JM, Gallo-González V, Ali-García I, Matesanz-Ruiz C, López-de-Andrés A, Jiménez-García R, Buendía-García MJ, Gómez-Sacristán Á, Girón-Matute WI, Puente-Maestu L, de Miguel-Díez J. Influence of Comorbidities on the Survival of COPD Patients According to Phenotypes. Int J Chron Obstruct Pulmon Dis 2020;15:2759-67. [PMID: 33154636 DOI: 10.2147/COPD.S270770] [Reference Citation Analysis]
45 Rogliani P, Ritondo BL, Laitano R, Chetta A, Calzetta L. Advances in understanding of mechanisms related to increased cardiovascular risk in COPD. Expert Rev Respir Med 2021;15:59-70. [PMID: 33084434 DOI: 10.1080/17476348.2021.1840982] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Korça E, Piskovatska V, Börgermann J, Navarrete Santos A, Simm A. Circulating antibodies against age-modified proteins in patients with coronary atherosclerosis. Sci Rep 2020;10:17105. [PMID: 33051525 DOI: 10.1038/s41598-020-73877-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
47 Deshmukh K, Khanna A. Implications of Managing Chronic Obstructive Pulmonary Disease in Cardiovascular Diseases. Tuberc Respir Dis (Seoul) 2021;84:35-45. [PMID: 33045814 DOI: 10.4046/trd.2020.0088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
48 Sandhaus R, Strange C, Stone G, Runken MC, Blanchette CM, Howden R. Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US. Int J Chron Obstruct Pulmon Dis 2020;15:2389-97. [PMID: 33116454 DOI: 10.2147/COPD.S263297] [Reference Citation Analysis]
49 Li J, Wang Q, Zhang Q, Wang Z, Wan X, Miao C, Zeng X. Higher Blood Vascular Cell Adhesion Molecule-1 is Related to the Increased Risk of Cardiovascular Events in Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2020;15:2289-95. [PMID: 33061346 DOI: 10.2147/COPD.S264889] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Matsunaga K, Harada M, Suizu J, Oishi K, Asami-Noyama M, Hirano T. Comorbid Conditions in Chronic Obstructive Pulmonary Disease: Potential Therapeutic Targets for Unmet Needs. J Clin Med 2020;9:E3078. [PMID: 32987778 DOI: 10.3390/jcm9103078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
51 Jafar Z, Valero-Elizondo J, Saeed GJ, Acquah I, Yahya T, Mahajan S, Mszar R, Khan SU, Caínzos-Achirica M, Nasir K. Association of cardiovascular risk profile with healthcare expenditure and resource utilization in chronic obstructive pulmonary disease, with and without atherosclerotic cardiovascular disease. Am J Prev Cardiol 2020;3:100084. [PMID: 34327464 DOI: 10.1016/j.ajpc.2020.100084] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Dimitrova M, Kamusheva M, Tachkov K, Mitov K, Doneva M, Pencheva V, Petrova D, Georgiev O, Stoitchkov J, Petrova G. Cardiovascular co-morbidity in patients with COPD in Bulgaria. Biotechnology & Biotechnological Equipment 2020;34:918-24. [DOI: 10.1080/13102818.2020.1810591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Stemmer A, Shadmi R, Bregman-Amitai O, Chettrit D, Blagev D, Orlovsky M, Deutsch L, Elnekave E. Using machine learning algorithms to review computed tomography scans and assess risk for cardiovascular disease: Retrospective analysis from the National Lung Screening Trial (NLST). PLoS One 2020;15:e0236021. [PMID: 32745082 DOI: 10.1371/journal.pone.0236021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
54 Riesco JA, Hidalgo M, Chipayo D, Gómez JJ, Zaragozá F. Profile of Cardiovascular Disease Patients Who are Diagnosed with COPD in a Smoking-Cessation Unit. Adv Ther 2020;37:3562-70. [PMID: 32588373 DOI: 10.1007/s12325-020-01403-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
55 Ioakeim-Skoufa I, Poblador-Plou B, Carmona-Pírez J, Díez-Manglano J, Navickas R, Gimeno-Feliu LA, González-Rubio F, Jureviciene E, Dambrauskas L, Prados-Torres A, Gimeno-Miguel A. Multimorbidity Patterns in the General Population: Results from the EpiChron Cohort Study. Int J Environ Res Public Health 2020;17:E4242. [PMID: 32545876 DOI: 10.3390/ijerph17124242] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
56 Ponomaryova AA, Rykova EY, Azhikina TL, Bondar AA, Cheremisina OV, Rodionov EO, Boyarko VV, Laktionov PP, Cherdyntseva NV. Long interspersed nuclear element-1 methylation status in the circulating DNA from blood of patients with malignant and chronic inflammatory lung diseases. Eur J Cancer Prev 2021;30:127-31. [PMID: 32516173 DOI: 10.1097/CEJ.0000000000000601] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
57 Day NC, Kumar S, Criner G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kaisermann MC, Kilbride S, Lange P, Lomas DA, Martin N, Martinez FJ, Singh D, Wise R, Lipson DA. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. Respir Res 2020;21:139. [PMID: 32503599 DOI: 10.1186/s12931-020-01398-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
58 Sun F, Franks K, Murray L, Lilley J, Wheller B, Banfill K, McWilliam A, Abravan A, Van Herk M, Faivre-Finn C, Cubbon R. Cardiovascular mortality and morbidity following radical radiotherapy for lung cancer: Is cardiovascular death under-reported? Lung Cancer 2020;146:1-5. [PMID: 32460218 DOI: 10.1016/j.lungcan.2020.05.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
59 Cavailles A, Melloni B, Motola S, Dayde F, Laurent M, Le Lay K, Caumette D, Luciani L, Lleu PL, Berthon G, Flament T. Identification of Patient Profiles with High Risk of Hospital Re-Admissions for Acute COPD Exacerbations (AECOPD) in France Using a Machine Learning Model. Int J Chron Obstruct Pulmon Dis 2020;15:949-62. [PMID: 32431495 DOI: 10.2147/COPD.S236787] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
60 Ambatiello LG, Chazova IE. [Cardiovascular and chronic obstructive pulmonary diseases: pathophysiological processes and treatment tactics]. Ter Arkh 2020;92:78-83. [PMID: 32598797 DOI: 10.26442/00403660.2020.03.000456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Marushchak M, Maksiv K, Krynytska I, Dutchak O, Behosh N. The Severity of Oxidative Stress in Comorbid Chronic Obstructive Pulmonary Disease (COPD) and Hypertension: Does it Depend On ACE and AGT Gene Polymorphisms? J Med Life 2019;12:426-34. [PMID: 32025262 DOI: 10.25122/jml-2019-0108] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
62 Sharan RN, Chanu TM, Chakrabarty TK, Farsalinos K. Patterns of tobacco and e-cigarette use status in India: a cross-sectional survey of 3000 vapers in eight Indian cities. Harm Reduct J 2020;17:21. [PMID: 32228623 DOI: 10.1186/s12954-020-00362-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
63 Szylińska A, Kotfis K, Listewnik M, Brykczyński M, Marra A, Rotter I. The burden of chronic obstructive pulmonary disease in open heart surgery-a retrospective cohort analysis of postoperative complications: STROBE compliant. Medicine (Baltimore) 2020;99:e19675. [PMID: 32221097 DOI: 10.1097/MD.0000000000019675] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
64 Haug N, Deischinger C, Gyimesi M, Kautzky-Willer A, Thurner S, Klimek P. High-risk multimorbidity patterns on the road to cardiovascular mortality. BMC Med 2020;18:44. [PMID: 32151252 DOI: 10.1186/s12916-020-1508-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
65 Axson EL, Ragutheeswaran K, Sundaram V, Bloom CI, Bottle A, Cowie MR, Quint JK. Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis. Respir Res 2020;21:54. [PMID: 32059680 DOI: 10.1186/s12931-020-1312-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
66 Zvizdic F, Begic E, Mujakovic A, Hodzic E, Prnjavorac B, Bedak O, Custovic F, Bradaric H, Durak-Nalbantic A. Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease. Med Arch 2019;73:72-5. [PMID: 31391690 DOI: 10.5455/medarh.2019.73.72-75] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
67 Hogea SP, Tudorache E, Fildan AP, Fira-Mladinescu O, Marc M, Oancea C. Risk factors of chronic obstructive pulmonary disease exacerbations. Clin Respir J 2020;14:183-97. [PMID: 31814260 DOI: 10.1111/crj.13129] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
68 Wshah A, Selzler AM, Hill K, Brooks D, Goldstein R. Determinants of Sedentary Behaviour in Individuals with COPD: A Qualitative Exploration Guided by the Theoretical Domains Framework. COPD 2020;17:65-73. [PMID: 31909650 DOI: 10.1080/15412555.2019.1708883] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
69 König R, Cao X, Oswald M, Forstner C, Rohde G, Rupp J, Witzenrath M, Welte T, Kolditz M, Pletz M; CAPNETZ study group. Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning. Eur Respir J 2019;54:1900824. [PMID: 31537702 DOI: 10.1183/13993003.00824-2019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
70 Marushchak M, Maksiv K, Krynytska I. ACE gene I/D polymorphism and arterial hypertension in patients with COPD. Pneumologia 2019;68:114-9. [DOI: 10.2478/pneum-2019-0039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
71 Jenkins C. Too little, too late? The underuse of beta-blockers in COPD needs evidence to address clinical uncertainty. Respirology 2020;25:122-3. [PMID: 31591800 DOI: 10.1111/resp.13702] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 Heraganahally SS, Wasgewatta SL, McNamara K, Eisemberg CC, Budd RC, Mehra S, Sajkov D. Chronic Obstructive Pulmonary Disease In Aboriginal Patients Of The Northern Territory Of Australia: A Landscape Perspective. Int J Chron Obstruct Pulmon Dis 2019;14:2205-17. [PMID: 31576117 DOI: 10.2147/COPD.S213947] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
73 Sharma H, Kapur P, Jalali RK, Dubey K. Atherosclerosis risk assessment in patients with chronic obstructive pulmonary disease: a case-control study. Ther Clin Risk Manag 2019;15:1061-71. [PMID: 31695395 DOI: 10.2147/TCRM.S216180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
74 Aldabayan YS, Ridsdale HA, Alrajeh AM, Aldhahir AM, Lemson A, Alqahtani JS, Brown JS, Hurst JR. Pulmonary rehabilitation, physical activity and aortic stiffness in COPD. Respir Res 2019;20:166. [PMID: 31340825 DOI: 10.1186/s12931-019-1135-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
75 Belenkov YN, Tsvetkova OA, Privalova EV, An GV, Ilgisonis IS, Voronkova OO. [Comorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern β-Adrenoblockers]. Kardiologiia 2019;59:48-55. [PMID: 31242841 DOI: 10.18087/cardio.2019.6.n458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
76 Crisan L, Wong N, Sin DD, Lee HM. Karma of Cardiovascular Disease Risk Factors for Prevention and Management of Major Cardiovascular Events in the Context of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Front Cardiovasc Med 2019;6:79. [PMID: 31294030 DOI: 10.3389/fcvm.2019.00079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
77 Leong P, MacDonald MI, Ko BS, Lau KK, Troupis JM, Bardin PG. Single-breath comprehensive cardiopulmonary assessment utilizing computerized tomography. Respirology 2019;24:1026-9. [PMID: 31099957 DOI: 10.1111/resp.13577] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
78 López-campos JL, Carrasco Hernández L, Quintana Gallego E. El dilema entre el pulmón y el corazón en EPOC: historia de dos ciudades. Archivos de Bronconeumología 2019;55:185-6. [DOI: 10.1016/j.arbres.2018.10.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
79 Leong P, Macdonald MI, Ko BS, Bardin PG. Coexisting chronic obstructive pulmonary disease and cardiovascular disease in clinical practice: a diagnostic and therapeutic challenge. Medical Journal of Australia 2019;210:417-23. [DOI: 10.5694/mja2.50120] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
80 de Vries M, Axson EL, Ratanachina J, Dumas O, De Matteis S, Bédard A, Roda C, Moitra S, Dagli E, Dimanti A, Dilektasli AG, Ravara S, Amaral AFS. European Respiratory Society International Congress 2018: four shades of epidemiology and tobacco control. ERJ Open Res 2019;5:00217-2018. [PMID: 30847352 DOI: 10.1183/23120541.00217-2018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
81 Gulea C, Zakeri R, Quint JK. Effect of beta-blocker therapy on clinical outcomes, safety, health-related quality of life and functional capacity in patients with chronic obstructive pulmonary disease (COPD): a protocol for a systematic literature review and meta-analysis with multiple treatment comparison. BMJ Open 2018;8:e024736. [PMID: 30429149 DOI: 10.1136/bmjopen-2018-024736] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
82 Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev 2018;27:180057. [PMID: 30282634 DOI: 10.1183/16000617.0057-2018] [Cited by in Crossref: 71] [Cited by in F6Publishing: 86] [Article Influence: 17.8] [Reference Citation Analysis]
83 Malo de Molina R, Aguado S, Arellano C, Valle M, Ussetti P. Ischemic Heart Disease during Acute Exacerbations of COPD. Med Sci (Basel) 2018;6:E83. [PMID: 30257486 DOI: 10.3390/medsci6040083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
84 Grymonprez M, Vakaet V, Kavousi M, Stricker BH, Ikram MA, Heeringa J, Franco OH, Brusselle GG, Lahousse L. Chronic obstructive pulmonary disease and the development of atrial fibrillation. Int J Cardiol 2019;276:118-24. [PMID: 30268382 DOI: 10.1016/j.ijcard.2018.09.056] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]